Celldex Therapeutics, Inc. (CLDX) · Nov 5, 2026 · Earnings
Beat — EPS $(0.96) vs ~$1.02 consensus; revenue $0 vs ~$0.72M consensus
Celldex’s third-quarter earnings modestly beat EPS expectations, while rising barzolvolimab spending and cash through 2028 reinforce the pivotal launch buildout.
Celldex is now a late-stage immunology company built around barzolvolimab: its two Phase 3 chronic spontaneous urticaria trials already delivered positive topline results in September, with treatment continuing to 52 weeks and a BLA submission planned for 2027.
The quarter modestly beat the financial bar, but not because the business is generating revenue. Third-party estimates pointed to roughly $(1.02) of quarterly EPS and $0.72 million of revenue; Celldex delivered $(0.96) EPS but no revenue. The EPS beat is the clean positive, while the revenue miss is economically minor for a company still pre-commercial. The filing itself says, “No material revenue was recognized in the third quarter of 2026.” 〔0〕
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Total revenue (Financial Highlights) | $0.0M | $0.0M | ~$0.72M |
| R&D expense (Financial Highlights) | $67.4M | $62.9M | |
| Net loss per share (Net Loss) | $(0.96) | $(1.01) | ~$(1.02) |
| Cash, equivalents and securities (Cash Position) | $650.3M | $518.6M* |
*December 31, 2025 comparison.
Higher spending is mostly the expected cost of advancing the lead asset. R&D rose to $67.4 million from $62.9 million as clinical-trial and manufacturing costs for barzolvolimab increased, while G&A rose to $14.8 million as Celldex expanded commercial planning. The release states, “The increase in R&D expenses was primarily due to an increase in barzolvolimab clinical trial and contract manufacturing expense.” 〔1〕 This is not a new operating problem; it is the financial consequence of moving from clinical validation toward a potential 2027 launch.
Funding remains a meaningful support for the story, but this is confirmation rather than fresh runway. Cash fell from $717.6 million at June 30 to $650.3 million at September 30 after $65.0 million of operating cash use, yet management maintained that existing resources can fund planned operations through 2028. The filing says, “Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2026 are sufficient to meet estimated working capital requirements and fund current planned operations through 2028.” 〔2〕 That was already the stated position in the prior quarter, so the update reduces near-term financing concern but does not materially change the strategic outlook.
The clinical investment case was largely decided before this filing. The September Phase 3 CSU readout met the primary and key secondary endpoints in both studies, so this 8-K adds little new efficacy information; it mainly shows the company spending into the next stage while preserving its 2028 cash target.
Bottom line: This is a narrow earnings beat and a reassuring funding update, not a new clinical catalyst. It modestly strengthens execution around an already-established barzolvolimab story, while revenue remains effectively nonexistent and spending continues to rise.更
Phase 2 atopic dermatitis data expected late 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!